Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

21, 2025 -- The FDA has approved a new treatment for patients ... Breast cancer is the most common cancer (after skin cancer) and the second leading cause of cancer death among women in the ...

The new indications, approved Tuesday by the FDA, make Ozempic the most broadly indicated drug in its class, with the largest set of specific medical conditions that it may be prescribed to treat.

(WDRB) -- Start 2025 in the right way by pampering yourself. WDRB's Keith Kaiser stopped by Purple Pearl Skin & Beauty in New Albany for some special treatments. Purple Pearl Skin & Beauty is a ...

Pearl Milling was originally branded as Aunt Jemima before 2021. On Thursday, the FDA updated the recall category to Class I, which pertains to "situation[s] in which there is a reasonable ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Novo Nordisk (NYSE:NVO) just scored a game-changing FDA approval for Ozempic, expanding its use beyond diabetes to tackle chronic kidney disease and cardiovascular risks. The move solidifies ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ...

Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD.